Literature DB >> 6388818

High-dose chemotherapy and non-frozen autologous bone marrow transplantation in relapsed advanced lymphomas or those resistant to conventional chemotherapy.

A M Carella, G Santini, D Giordano, F Frassoni, S Nati, A Congiu, D Occhini, E Rossi, M Martinengo, E Damasio.   

Abstract

Ten patients with advanced, diffuse Hodgkin's and non-Hodgkin's lymphomas responding poorly to the most widely employed primary chemotherapy regimens were treated with a high-dose chemotherapy (HDC) followed by rescue with non-frozen autologous bone marrow infusion (ABMT). Complete remission (CR) was obtained in seven of ten patients (70%) and partial remission in two. Hemopoietic recovery occurred in nine cases. These preliminary results appear to indicate that HDC and non-frozen ABMT may be successfully used in patients with resistant or relapsed lymphomas.

Entities:  

Mesh:

Year:  1984        PMID: 6388818     DOI: 10.1002/1097-0142(19841215)54:12<2836::aid-cncr2820541203>3.0.co;2-r

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  3 in total

1.  Intensive chemotherapy with high doses of BCNU, etoposide, cytosine arabinoside, and melphalan (BEAM) followed by autologous bone marrow transplantation: toxicity and antitumor activity in 26 patients with poor-risk malignancies.

Authors:  M H Gaspard; D Maraninchi; A M Stoppa; J A Gastaut; G Michel; N Tubiana; D Blaise; G Novakovitch; J F Rossi; P J Weiller
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

2.  Frozen vs. nonfrozen bone marrow for autologous transplantation in lymphomas: a report from the Spanish GEL/TAMO Cooperative Group.

Authors:  J Sierra; E Conde; A Iriondo; S Brunet; J Marín; J Pérez de Oteiza; D Caballero; F Martínez; A León; J García-Conde
Journal:  Ann Hematol       Date:  1993-09       Impact factor: 3.673

3.  High dose chemotherapy and autologous bone marrow transplantation in refractory Hodgkin's disease.

Authors:  T Philip; J Dumont; F Teillet; D Maraninchi; N C Gorin; M Kuentz; J L Harousseau; M Marty; R Pinkerton; P Herve
Journal:  Br J Cancer       Date:  1986-06       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.